A share price of Altimmune Inc [ALT] is currently trading at $4.62, up 9.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALT shares have gain 15.21% over the last week, with a monthly amount drifted -8.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On January 08, 2025, Stifel initiated with a Buy rating and assigned a price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $26 on November 12, 2024. Guggenheim downgraded its rating to a Neutral. Goldman started tracking with a Neutral rating for this stock on January 24, 2024, and assigned it a price target of $13. In a note dated March 22, 2023, Goldman downgraded an Neutral rating on this stock and revised its target price from $20 to $6.
Altimmune Inc experienced fluctuations in its stock price throughout the past year between $2.90 and $7.73. Currently, Wall Street analysts expect the stock to reach $23.6 within the next 12 months. Altimmune Inc [NASDAQ: ALT] shares were valued at $4.62 at the most recent close of the market. An investor can expect a potential return of 410.82% based on the average ALT price forecast.
Analyzing the ALT fundamentals
Gross Profit Margin for this corporation currently stands at -747.0% with Operating Profit Margin at -4523.1%, Pretax Profit Margin comes in at -4229.8%, and Net Profit Margin reading is -4195.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.55 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Altimmune Inc [NASDAQ:ALT] is 17.18. In addition, the Quick Ratio stands at 17.18 and the Cash Ratio stands at 4.86. Considering the valuation of this stock, the price to sales ratio is 24103.18, the price to book ratio is 2.38.
Transactions by insiders
Recent insider trading involved Pisano Wayne, Director, that happened on Jan 08 ’26 when 5000.0 shares were purchased. Director, Jorkasky Diane completed a deal on Dec 29 ’25 to buy 527.0 shares. Meanwhile, Director GILL JOHN bought 12500.0 shares on Dec 23 ’25.
